(+)-Etomoxir sodium
CAS: 828934-41-4
Ref. 3D-FE63597
| 2mg | Discontinued | ||
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued | ||
| 50mg | Discontinued |
Product Information
- (2R)-2-[6-(4-Chlorophenoxy)hexyl]-oxiranecarboxylic acid sodium
- (+)-Etomoxir Sodium Hydrate
- (+)-Etomoxir hydrate sodium salt
- 2-Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, sodium salt (1:1), (2R)-
- Anti-eapii (ttrap)
- Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, sodium salt, (2R)-
- R(+)-2-[6-(4-Chlorophenoxy)Hexyl]-Oxirane-2-Carboxylic Acid Sodium Salt Hydrate
- R(+)-2-[6-(4-Chlorophenoxy)hexyl]-oxirane-2-carboxylic
- sodium (2R)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate hydrate
Etomoxir sodium is a fatty acid derivative that has been shown to be a potent, selective, and reversible inhibitor of the enzyme carnitine palmitoyltransferase 1 (CPT1). This drug inhibits the conversion of long chain fatty acids into acyl-CoA esters in the mitochondria. Etomoxir sodium has been studied in clinical trials for the treatment of diabetic neuropathy and HIV infection. It also has been shown to inhibit cancer cell proliferation and cardiac hypertrophy. The mechanism of action is unknown, but it may be due to its ability to inhibit carnitine uptake into cells or by affecting cellular energy metabolism. Etomoxir sodium is a strong base and should not be handled with hydroxide solution unless activated first by adding a small amount of water or hydrochloric acid.
